The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.
Cancer vaccines based on antigens derived from self molecules rather than pathogens have been under basic and clinical investigations for many years. Up until very recently, they had been tested primarily in the setting of metastatic disease with the goal to engage the immune system in slowing down disease progression. Many therapeutic vaccine trials, either investigator initiated or led by pharmaceutical companies, have been completed and many are currently ongoing, following the FDA Guidance on therapeutic cancer vaccines published in 2011. In recent years, the target of cancer vaccines is being shifted to early cancer and even premalignant disease with the goal of preventing cancer. Although some issues addressed in the FDA Guidance on therapeutic vaccines apply to preventive vaccines, many do not. Here, we discuss a set of recommendations for revising the current Guidance to also cover preventive vaccines, or to include in a new Guidance dedicated specifically to vaccines for cancer prevention.
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. ojfinn@pitt.edu.
Olivera J
OJ
Finn
GRU Cancer Center, Georgia Regent University, Augusta, Georgia.
Samir N
SN
Khleif
Ronald B
RB
Herberman
D019496:Cancer Vaccines / Q000592:standards* / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D007107:Immune System; D008495:Medical Oncology / Q000592:standards; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
D019496:Cancer Vaccines